

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8368480

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	NANT HOLDINGS IP, LLC	12/25/2023
RECEIVING PARTY DATA		
Name:	IMMUNITYBIO, INC.	
Street Address:	9920 JEFFERSON BOULEVARD	
City:	CULVER CITY	
State/Country:	CALIFORNIA	
Postal Code:	90232	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17750768
CORRESPONDENCE DATA		
Fax Number:	(314)726-7501	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	3147267500	
Email:	lmrefile@harnessip.com	
Correspondent Name:	LEANNE M. RAKERS	
Address Line 1:	HARNESS DICKEY & PIERCE	
Address Line 2:	7700 BONHOMME AVE., SUITE 400	
Address Line 4:	SAINT LOUIS, MISSOURI 63105	
ATTORNEY DOCKET NUMBER:	17768NH-000006-US	
NAME OF SUBMITTER:	LEANNE M. RAKERS	
SIGNATURE:	/LEANNE M. RAKERS/	
DATE SIGNED:	01/08/2024	
Total Attachments: 2		
source=NH to IBRX - PATENT ASSIGNMENT 12.28.23 FINAL#page1.tif		
source=NH to IBRX - PATENT ASSIGNMENT 12.28.23 FINAL#page2.tif		

PATENT ASSIGNMENT

NANT HOLDINGS IP, LLC, a limited liability company under the laws of the State of Delaware, having a place of business at 9920 Jefferson Boulevard, Culver City, CA 90232 (the "Assignor"), desires to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to IMMUNITYBIO, INC. a corporation incorporated under the laws of the State of Delaware, having a place of business 9920 Jefferson Boulevard, Culver City, CA 90232, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor has obtained the entire right, title and interest in and to certain new and useful inventions and improvements disclosed in the U.S. and foreign patent(s) and pending patent application(s) listed on Schedule A hereto (the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(c). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

3. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.

4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, and assigns, and shall be binding upon said Assignor and its assigns.

5. Said Assignor hereby warrants, represents and covenants that Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.


6. Said Assignor hereby requests that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors and assigns.

7. This instrument will be interpreted and construed in accordance with the laws of the State of Delaware, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below:


AGREED TO BY ASSIGNOR (NANT HOLDINGS IP, LLC):

Date: 12/28/2023

Signature: 
Name: Charles M. Kenworthy
Title: Manager

RECEIVED AND AGREED TO BY ASSIGNEE (IMMUNITYBIO, INC.):

Date: 12/28/2023

Signature: 
Name: David Romero
Title: V.P. Senior Corporate Counsel

PATENT ASSIGNMENT

Schedule A

Reference No.	Jurisdictions	Patent Application Number	Patent Number
PAT.005343.US002	United States of America	18/509,777	
PAT.005343.WO001	Patent Cooperation Treaty (PCT)	PCT/US2023/079675	
PAT.000408.AU001	Australia	2016366183	2016366183
PAT.000408.AU002	Australia	2019280006	2019280006
PAT.000408.CA001	Canada	3,007,656	
PAT.000408.CN001	China	201680077972.8	
PAT.000408.IL001	Israel	259894	
PAT.000408.JP001	Japan	2018-549145	7034931
PAT.000408.MX001	Mexico	MX/A/2018/006996	383966
PAT.000408.TW001	Taiwan, Republic of China	105140301	I733719
PAT.000408.US001	United States of America	16/060,020	10,793,875
PAT.000408.US003	United States of America	16/836,515	11,441,160
PAT.000428.US001	United States of America	15/366,838	10,533,157
PAT.000428.US003	United States of America	16/702,275	11,725,186
PAT.000428.US004	United States of America	18/339,014	
PAT.000763.AU001	Australia	2018214558	2018214558
PAT.001009.US002	United States of America	17/041,377	11,267,866
PAT.001009.US003	United States of America	17/588,949	
PAT.001284.US002	United States of America	16/381,837	11,823,773
PAT.001284.US003	United States of America	18/480,149	
PAT.005079.US002	United States of America	16/925,141	
PAT.005224.US002	United States of America	17/215,265	
PAT.005254.US002	United States of America	17/392,683	
PAT.005266.US003	United States of America	18/194,004	
PAT.005277.CN001	China	To be filed	
PAT.005277.EP001	European Patent Office (EPO)	To be filed	
PAT.005277.US002	United States of America	17/750,768	
PAT.005277.WO001	Patent Cooperation Treaty (PCT)	PCT/US2022/030473	
PAT.005277.ZA001	South Africa	2023/10569	
PAT.005328.US002	United States of America	63/517,015	
PAT.005332.WO001	Patent Cooperation Treaty (PCT)	PCT/US2023/028485	
PAT.005353.US001	United States of America	63/512,032	
PAT.005353.US002	United States of America	63/515,528	
PAT.005353.US003	United States of America	63/605,326	
PAT.005354.US001	United States of America	63/515,444	
PAT.005355.US001	United States of America	To be filed	
PAT.005356.US001	United States of America	63/587,008	
PAT.005362.US001	United States of America	63/596,583	